Erratum to: “Reduced-Intensity Conditioning Combined with 188Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of in Vivo T Cell Depletion” [Biol Blood Marrow Transplant (2015) 21 (1754–1760)] (S1083879115003353)(10.1016/j.bbmt.2015.05.012);Reduced-Intensity Conditioning Combined with 188Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 10, 2015, Pages 1754-1760

  Schneider, Sebastian ^a   Strumpf, Annette ^a   Schetelig, Johannes ^a   Wunderlich, Gerd ^a   Ehninger, Gerhard ^a   Kotzerke, Jörg ^a   Bornhäuser, Martin ^a,b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b German Consortium for Translational Cancer Research   (Germany)

Author keywords

Acute myeloid leukemia; Alemtuzumab; Re 188 radioimmunotherapy; Reduced intensity conditioning; Stem cell transplantation

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BUSULFAN; COTRIMOXAZOLE; CYCLOSPORIN A; FLUDARABINE; GANCICLOVIR; RHENIUM 188; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CD66 ANTIGENS; CELL ADHESION MOLECULE; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; RADIOISOTOPE; RHENIUM; TUMOR ANTIGEN; VIDARABINE;

ACUTE KIDNEY FAILURE; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IN VIVO STUDY; LENGTH OF STAY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RADIOIMMUNOTHERAPY; REDUCED INTENSITY CONDITIONING; T CELL DEPLETION; TREATMENT DURATION; TREATMENT RESPONSE; ADVERSE EFFECTS; ALLOGRAFT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; FEASIBILITY STUDY; GRAFT VERSUS LEUKEMIA EFFECT; GRAFT VS HOST DISEASE; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE DEPLETION; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; PROCEDURES; T LYMPHOCYTE; TRANSPLANTATION CONDITIONING;

AGED; ALLOGRAFTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CELL ADHESION MOLECULES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HUMANS; IMMUNOCONJUGATES; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; PROSPECTIVE STUDIES; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RHENIUM; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 84941318001     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2016.12.626     Document Type: Erratum

References (34)

1. Dohner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
2. Fey M.F., Dreyling M. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v158-v161. ESMO Guidelines Working Group.
3. Scott B.L., Deeg H.J. Myelodysplastic syndromes. Annu Rev Med 2010, 61:345-358.
4. Cornelissen J.J., van Putten W.L., Verdonck L.F., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 2007, 109:3658-3666.
5. Yanada M., Matsuo K., Emi N., Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005, 103:1652-1658.
6. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
7. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579-585.
8. Burnett A.K., Wheatley K., Goldstone A.H., et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002, 118:385-400.
9. Gale R.P., Horowitz M.M. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1990, 6(Suppl 1):94-97.
10. Anderson J.E., Appelbaum F.R., Fisher L.D., et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993, 82:677-681.
11. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997, 80:1273-1283.
12. Grimwade D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1312-1320.
13. Nash R.A., Pepe M.S., Storb R., et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992, 80:1838-1845.
14. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004, 104:961-968.
15. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
16. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005, 19:2304-2312.
17. Bunjes D., Buchmann I., Duncker C., et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood 2001, 98:565-572.
18. Koenecke C., Hofmann M., Bolte O., et al. Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia. Int J Hematol 2008, 87:414-421.
19. Lauter A., Strumpf A., Platzbecker U., et al. 188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation. Br J Haematol 2010, 148:910-917.
20. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
21. Kotzerke J., Glatting G., Seitz U., et al. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs. J Nucl Med 2000, 41:531-537.
22. Buchmann I., Bunjes D., Kotzerke J., et al. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities. Cancer Biother Radiopharm 2002, 17:151-163.
23. Hale G., Jacobs P., Wood L., et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000, 26:69-76.
24. Kottaridis P.D., Milligan D.W., Chopra R., et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000, 96:2419-2425.
25. Thiede C., Florek M., Bornhauser M., et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999, 23:1055-1060.
26. Cheson B.D., Cassileth P.A., Head D.R., et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990, 8:813-819.
27. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
28. Sullivan K.M., Agura E., Anasetti C., et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991, 28:250-259.
29. Lin D.Y. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997, 16:901-910.
30. Rezvani K., Yong A.S., Savani B.N., et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007, 110:1924-1932.
31. Rebello P., Cwynarski K., Varughese M., et al. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001, 3:261-267.
32. Pagel J.M., Appelbaum F.R., Eary J.F., et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006, 107:2184-2191.
33. McDevitt M.R., Ma D., Lai L.T., et al. Tumor therapy with targeted atomic nanogenerators. Science 2001, 294:1537-1540.
34. Jurcic J.G., Larson S.M., Sgouros G., et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002, 100:1233-1239.